U. Argikar

发表

Effect of Aging on Glucuronidation of Valproic Acid in Human Liver Microsomes and the Role of UDP-Glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10

R. Remmel, U. Argikar, 2009, Drug Metabolism and Disposition.

Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery.

Jianling Wang, Liping Zhou, U. Argikar, 2011, Analytical chemistry.

Enzyme Kinetics in Drug Metabolism

D. Tweedie, S. Nagar, U. Argikar, 2014, Methods in Molecular Biology.

Identification of saturated and unsaturated fatty acids released during microsomal incubations

U. Argikar, J. Bushee, Guiqing Liang, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

Variation in glucuronidation of lamotrigine in human liver microsomes

R. Remmel, U. Argikar, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients

A. Birnbaum, W. Oetting, I. Leppik, 2006, Epilepsy Research.

Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

J. Miners, Jin Zhou, U. Argikar, 2021, Methods in molecular biology.

Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route

V. Sasseville, M. Walles, G. Camenisch, 2018, Drug Metabolism and Disposition.

Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species.

U. Argikar, J. Mangold, S. Harriman, 2011, Current topics in medicinal chemistry.

Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.

Scott A. Busby, Daniel S. Palacios, W. Weihofen, 2017, Bioorganic & medicinal chemistry letters.

Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.

Y. Yagi, Mitsunori Kato, Monish Jain, 2017, Journal of medicinal chemistry.

Novel advances in biotransformation and bioactivation research – 2020 year in review

G. Miller, A. Kalgutkar, I. Rietjens, 2021, Drug metabolism reviews.

Biotransformation novel advances – 2021 year in review

A. Kalgutkar, Kevin Johnson, Lloyd King, 2022, Drug metabolism reviews (Softcover ed.).

Bioactivation and reactivity research advances – 2021 year in review

G. Miller, J. Driscoll, Lloyd King, 2022, Drug metabolism reviews.

UDP-Glucuronosyltransferases

U. Argikar, R. Foti, 2019, Handbook of Drug Metabolism.

Comparative Proteomics Analysis of the Postmitochondrial Supernatant Fraction of Human Lens-Free Whole Eye and Liver S

U. Argikar, Saranjit Singh, Ankit Balhara, 2021 .

Compound Property Optimization in Drug Discovery Using Quantitative Surface Sampling Micro Liquid Chromatography with Tandem Mass Spectrometry.

K. Mansfield, S. Hintermann, Adam Bentley, 2016, Analytical chemistry.

The mesentery: an ADME perspective on a ‘new’ organ

U. Argikar, Aneesh A Argikar, 2018, Drug metabolism reviews.

Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes

U. Argikar, Jennifer L. Dumouchel, C. Dunne, 2017, Drug metabolism reviews.

Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors.

D. Bednarczyk, Y. Cho, S. Skolnik, 2022, Journal of medicinal chemistry.

Studies on induction of lamotrigine metabolism in transgenic UGT1 mice

R. Tukey, R. Remmel, U. Argikar, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.

N. Gradoux, A. Vulpetti, B. Jaffee, 2019, Journal of medicinal chemistry.

Oxidative ipso Substitution of 2,4-Difluoro-benzylphthalazines: Identification of a Rare Stable Quinone Methide and Subsequent GSH Conjugate

F. Lombardo, U. Argikar, Amanda L. Cirello, 2012, Drug Metabolism and Disposition.

Unusual Glucuronides

U. Argikar, 2012, Drug Metabolism and Disposition.

Minireview Unusual Glucuronides

U. Argikar, 2012 .

In vitro ocular metabolism and bioactivation of ketoconazole in rat, rabbit and human.

U. Argikar, Jennifer L. Dumouchel, Amanda L. Cirello, 2017, Drug metabolism and pharmacokinetics.

Comparative Proteomics Analysis of the Postmitochondrial Supernatant Fraction of Human Lens-Free Whole Eye and Liver

A. Basit, U. Argikar, Saranjit Singh, 2021, Drug Metabolism and Disposition.

Understanding metabolism related differences in ocular efficacy of MGV354

M. Mogi, U. Argikar, Jennifer L. Dumouchel, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?

U. Argikar, Jennifer L. Dumouchel, Amanda L. Cirello, 2017, Journal of pharmaceutical sciences.

Ocular Metabolism of Levobunolol: Historic and Emerging Metabolic Pathways

Christine E. Dunne, U. Argikar, Mithat Gunduz, 2016, Drug Metabolism and Disposition.

An in vitro approach to investigate ocular metabolism of a topical, selective β1-adrenergic blocking agent, betaxolol

U. Argikar, C. Dunne, Jennifer L. Bushee, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

An experimental approach to enhance precursor ion fragmentation for metabolite identification studies: application of dual collision cells in an orbital trap.

U. Argikar, Jennifer L. Bushee, 2011, Rapid communications in mass spectrometry : RCM.

Identification of a Novel N-Carbamoyl Glucuronide: In Vitro, In Vivo, and Mechanistic Studies

U. Argikar, V. Hosagrahara, Suzie Ferreira, 2010, Drug Metabolism and Disposition.

Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

P. Potter, P. Marathe, J. M. Hutzler, 2016, The AAPS Journal.

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

Franco Lombardo, Giuliano Berellini, F. Lombardo, 2013, Journal of clinical pharmacology.

Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus*

R. Tukey, O. Barbier, J. Ritter, 2005, Journal of Biological Chemistry.

Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: applications for compounds with low solubility.

U. Argikar, V. Hosagrahara, Wendy Lee, 2011, Drug Metabolism and Pharmacokinetics.

Conjugative Metabolism of Drugs

R. Remmel, S. Nagar, U. Argikar, 2007 .

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Thomas M. Smith, N. Gradoux, Jian Ding, 2020, Journal of medicinal chemistry.

Implications for Metabolite Quantification by Mass Spectrometry in the Absence of Authentic Standards

N. Waters, U. Argikar, P. Hatsis, 2017, Drug Metabolism and Disposition.

Rapid, large‐scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver

Piero Rinaldo, Scott L Nyberg, S. Nyberg, 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes.

U. Argikar, C. Dunne, Jennifer L. Bushee, 2013, Drug metabolism and pharmacokinetics.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

Thomas M. Smith, F. Sirockin, B. Gerhartz, 2019, Proceedings of the National Academy of Sciences.

Microsoft Word-18199777-file00

U. Argikar, V. Hosagrahara, Suzie Ferreira, 2009 .

Expression of the Human UGT1 Locus in Transgenic Mice by 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid (WY-14643) and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor α Activation

R. Tukey, O. Barbier, J. Ritter, 2007, Drug Metabolism and Disposition.

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State

Franco Lombardo, R Scott Obach, Giuliano Berellini, 2013, Journal of clinical pharmacology.

Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.

S. Nagar, U. Argikar, O. Iwuchukwu, 2008, Expert opinion on drug metabolism & toxicology.

New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation

U. Argikar, Jennifer L. Dumouchel, Amanda L. Cirello, 2018, Drug metabolism letters.

Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.

Karen Anderson, Anna Vulpetti, Ulrich Hommel, 2017, Journal of medicinal chemistry.

Saccharolactone: The History, the Myth, and the Practice.

U. Argikar, 2017, Current drug metabolism.

Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies

H. Parkman, S. Nagar, U. Argikar, 2010, Drug Metabolism and Disposition.

Microsoft Word-75738300-file00

H. Parkman, S. Nagar, U. Argikar, 2010 .

Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes.

Jin Zhou, R. Remmel, U. Argikar, 2011, Pharmacogenomics.

Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC–ESI-MS/MS

H. Parkman, S. Nagar, U. Argikar, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms

S. Nagar, U. Argikar, O. Iwuchukwu, 2008, Expert opinion on drug metabolism & toxicology.

Enzyme kinetics in drug metabolism: fundamentals and applications.

D. Tweedie, S. Nagar, U. Argikar, 2014, Methods in molecular biology.

Investigation of Ocular Bioactivation Potential and the Role of Cytochrome P450 2D Enzymes in Rat.

U. Argikar, Jennifer L. Dumouchel, Amanda L. Cirello, 2018, Drug metabolism letters.

Bioactivation and reactivity research advances – 2022 year in review‡

G. Miller, A. Kalgutkar, Lloyd King, 2023, Drug metabolism reviews.

Industry Perspective on Therapeutic Peptide Drug–Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White Paper

A. Sonesson, Hilmar Schiller, U. Argikar, 2023, Clinical pharmacology and therapeutics.

Biotransformation research advances – 2022 year in review

U. Argikar, S. C. Khojasteh, H. Seneviratne, 2023, Drug metabolism reviews.

A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data

D. Tweedie, K. Korzekwa, Andrea Whitcher-Johnstone, 2014, Drug Metabolism and Disposition.

DMD058297 1587..1595

D. Tweedie, K. Korzekwa, Andrea Whitcher-Johnstone, 2014 .

Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route

V. Sasseville, M. Walles, G. Camenisch, 2018, Drug Metabolism and Disposition.

Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC–ESI-MS/MS

H. Parkman, S. Nagar, U. Argikar, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Genotoxicity of 4-(piperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-e][1,2,4] triazolo[4,3-a]pyrazine, a Potent H4 Receptor Antagonist for the Treatment of Allergy: Evidence of Glyoxal Intermediate Involvement.

P. Klimko, U. Argikar, Jennifer L. Dumouchel, 2018, Drug metabolism letters.